NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis $41.20 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$41.00 -0.21 (-0.50%) As of 07/2/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vera Therapeutics Stock (NASDAQ:VERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vera Therapeutics alerts:Sign Up Key Stats Today's Range$36.76▼$42.8050-Day Range$31.26▼$43.1552-Week Range$19.07▼$56.05Volume5.02 million shsAverage Volume1.79 million shsMarket Capitalization$2.96 billionP/E RatioN/ADividend YieldN/APrice Target$78.00Consensus RatingModerate Buy Company Overview Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates. The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.AI Generated. May Contain Errors. Read More Vera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreVERA MarketRank™: Vera Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 269th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVera Therapeutics has a consensus price target of $78.00, representing about 89.3% upside from its current price of $41.20.Amount of Analyst CoverageVera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vera Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vera Therapeutics are expected to grow in the coming year, from ($6.23) to ($4.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vera Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.61% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Vera Therapeutics has recently increased by 9.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.32 News SentimentVera Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vera Therapeutics this week, compared to 4 articles on an average week.Search Interest46 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 1,433% compared to the previous 30 days.MarketBeat Follows11 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,392,387.00 in company stock.Percentage Held by Insiders15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vera Therapeutics' insider trading history. Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERA Stock News HeadlinesIs Vera Therapeutics, Inc. (VERA) A Good Stock To Buy Now?July 3 at 10:07 PM | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 30, 2026 | americanbankingnews.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.July 4 at 1:00 AM | Behind the Markets (Ad)Marshall Fordyce Sells 18,500 Shares of Vera Therapeutics (NASDAQ:VERA) StockJune 26, 2026 | americanbankingnews.comInsider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells 18,500 Shares of StockJune 25, 2026 | insidertrades.com3 Biotech Firms With Major Potential Catalysts in the Coming MonthsThe pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.June 22, 2026 | marketbeat.comVera Therapeutics (VERA) Appears Attractive After Latest FDA AgreementJune 17, 2026 | finance.yahoo.comVera Therapeutics (VERA) Receives a Buy from Wells FargoJune 13, 2026 | theglobeandmail.comSee More Headlines VERA Stock Analysis - Frequently Asked Questions How have VERA shares performed this year? Vera Therapeutics' stock was trading at $50.64 at the start of the year. Since then, VERA stock has decreased by 18.6% and is now trading at $41.20. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) issued its earnings results on Thursday, May, 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by $0.36. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $65 million in an initial public offering on Thursday, May 13th 2021. The company issued 4,350,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings5/07/2026Today7/04/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 10 days, VERA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VERA CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees40Year Founded2016Price Target and Rating Average Price Target for Vera Therapeutics$78.00 High Price Target$110.00 Low Price Target$33.00 Potential Upside/Downside+89.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($5.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.86% Return on Assets-60.18% Debt Debt-to-Equity Ratio0.15 Current Ratio13.64 Quick Ratio13.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.48 per share Price / Book4.86Miscellaneous Outstanding Shares71,780,000Free Float60,370,000Market Cap$2.96 billion OptionableOptionable Beta0.92 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:VERA) was last updated on 7/4/2026 by MarketBeat.com Staff. From Our PartnersTwo Legends Issue Rare Buy Alert on Elon Musk SupplierJeff Brown and Marc Chaikin - the two investors who picked Nvidia before it climbed as much as 36,000% - are i...Brownstone Research | SponsoredHe turned $12,415 into millions. Now he wants to help you.Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...Tim Sykes | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | Sponsored**MARKET CRASH WARNING**A former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...Paradigm Press | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
